Join us at the ASTRO Annual Meeting
Booth 3457 | October 21 - 24, 2018
Henry B. Gonzalez Convention Center, San Antonio, TX
Breast Cancer Treatment in as Little as 1 Day
More than 3,000 Early Stage Breast Cancer Patients Treated with IORT
Non-Surgical Treatment for Skin Cancer
Redefining the Future of Non-Melanoma Skin Cancer Treatment
Gynecological Brachytherapy
for Endometrial and Cervical Applications
<
>
Precision therapy. Personalized care.
For us, it’s personal.
We are passionate about targeted cancer care expertly tailored to meet patients’ personalized needs. We carefully designed the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to empower physicians with full confidence to precisely and effectively treat cancer and enable patients to live healthy, high-quality lives.
From the Newsroom
October 9, 2018
SUNY Upstate Medical University Selects iCAD’s Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment
October 3, 2018
Sanford Health Announces Adoption of iCAD’s Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment
August 29, 2018
iCAD Announces AERB Approval of Xoft System in India
View all>
Breast IORT Case Study
Leading global centers select the Xoft System for treatment of early-stage breast cancer
Multiple factors including clinically-proven efficacy, shorter treatment time, greater flexibility, easy portability and lower cost drive adoption
Learn more>
Customer Spotlight
Medical City Plano, a HCA Healthcare Facility, becomes first in Texas to offer intraoperative radiation therapy with the advanced Xoft System to enhance patient care.
Learn more>
Clinical Data
Discover the growing body of favorable clinical data supporting the use of electronic brachytherapy (eBx) in patients meeting specific selection criteria.
Learn more>
Discover our Advanced, Multi-Platform System
<
Exceptional clinical innovation at your fingertips
Our passion for targeted cancer care starts at the source.
Our proprietary, miniaturized x-ray source is isotope-free and operates at 50 kV to deliver high dose rate, low energy radiation. The source is placed inside the applicator and energized to deliver a precise, prescribed dose of radiation.
Our versatile Xoft System utilizes electronic brachytherapy to provide expanded treatment options for a range of cancers.
The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers.
Intraoperative Radiation Therapy (IORT)
Explore a simplified alternative to traditional six-week radiation therapy for early-stage breast cancer treatment.
With the Xoft System, delivery of radiation therapy in the operating room at the time of surgery is possible with IORT. IORT may be utilized to deliver a single fraction or boost dose.
Skin eBx
Discover a non-invasive alternative to surgery for non-melanoma skin cancer (NMSC) treatment.
From the market leader in skin electronic brachytherapy, skin eBx provides an effective, non-surgical, convenient treatment option with excellent clinical and cosmetic results for appropriately selected patients.1 More than 10,000 NMSC patients have been successfully treated with skin eBx.
1. A Bhatnagar, et al. High-dose Rate Electronic Brachytherapy: A Nonsurgical Treatment Alternative for Nonmelanoma Skin Cancer. The Journal of Clinical and Aesthetic Dermatology; Nov. 2016; Vol.9; No.11: 16-22.
GYN eBx
With expertly designed applicators for both endometrial and cervical cancer treatment, the Xoft System offers a range of targeted gynecological cancer treatment options in a minimally shielded setting.
>
Empowering the successful treatment of more than 15,000 patients worldwide.
Speak to a specialist today at 1.877.963.8327
Products
Precision therapy. Personalized care.
©2018 Xoft®, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.
